|
Digi-Prex |
|
Online subscription pharmacy that deliver patients with chronic diseases their prescriptions. |
Seed |
USD 5,500,000 |
|
|
Babylon Health |
|
|
Series C |
USD 550,000,000 |
|
![[current-page:title] logo](/sites/default/files/styles/icon/public/default_images/_no-logo.png?itok=AH4pbDYM)
|
Shire PLC |
|
|
Acquisition |
|
|
|
1life Healthcare Inc |
|
A healthcare company focuses on designing innovative health care solutions. |
Series C |
USD 220,000,000 |
|
|
Cambridge Cancer Genomics Ltd |
|
CCG.ai empowers clinicians to make personalised treatment strategies. |
Seed |
|
|
|
Ginkgo Bioworks Inc |
|
DNA design company. |
Series D |
USD 275,000,000 |
|
|
|
4C Medical Technologies Inc |
|
Medical device company developing minimally invasive therapies for structural heart disease. |
Convertible Note |
USD 8,000,000 |
|
|
|
ABI Health |
|
|
Seed |
USD 1,500,000 |
|
|
|
Babylon Health |
|
|
Series B |
USD 47,000,000 |
|
|
NBE-Therapeutics AG |
|
Biotech company focused on developing antibody-based treatments for cancer patients. |
Series B |
CHF 20,000,000 |
|
|
|
Ginkgo Bioworks Inc |
|
DNA design company. |
Series C |
USD 100,000,000 |
|
|
|
Babylon Health |
|
|
Series A |
USD 25,000,000 |
|
|
|
1life Healthcare Inc |
|
A healthcare company focuses on designing innovative health care solutions. |
N/A |
USD 65,000,000 |
|
|
|
InterMune Inc |
|
Biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. |
Acquisition |
USD 8,300,000,000 |
|
|
|
Shire PLC |
|
|
Acquisition |
USD 54,800,000,000 |
|
|
|
ViroPharma Inc |
|
Provider of life-saving medicines for life-threatening diseases. |
Acquisition |
USD 495,000,000 |
|
|
Merck & Co |
|
|
Acquisition |
USD 14,200,000,000 |
|
|
|
Novartis Animal Health |
|
|
Acquisition |
USD 5,400,000,000 |
|
|
|
Questcor Pharmaceuticals Inc |
|
|
Acquisition |
USD 5,600,000,000 |
|
|
|
Neuros Medical Inc |
|
Focused on developing neurostimulation therapies based on Nerve Block for patients with chronic pain conditions |
Series B |
USD 4,000,000 |
|